Pipeline advancements and investment in innovation and disruptive technologies to help fuel sustainable, profitable growth for CSL's three businesses, CSL Behring, CSL Seqirus and CSL Vifor, in...

CSL Limited (ASX:CSL; USOTC:CSLLY) today announces that its subsidiary, CSL Seqirus, has entered into a collaboration and license agreement with Arcturus Therapeutics Holdings Inc ("Arcturus...

Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY), today announced the company has entered into a Strategic Option and License Agreement with Arizona-based Translational Sciences for their enhanced thrombus dissolving drug candidate, TS23.

Global biotechnology leader CSL’s new global corporate headquarters has been awarded a five-star rating from the Green Building Council of Australia.

Global biotherapeutics leader CSL today announced that two Australian scientists have each been awarded a CSL Centenary Fellowship of $1.25 million over five years.

CSL Extends Reach of Global Research Acceleration Initiative with Freshly Inked Partnerships to Fast-Track Research Programs

Bernadette Murdoch, an experienced Australian and global corporate affairs and communications leader across multiple industries, will join CSL and lead its global Reputation Management Center of...

The new facility, once fully open later this calendar year, will be CSL's largest R&D site under one roof, with more than 500 team members working in a state-of-the-art facility offering access to...

CSL Limited (ASX: CSL) Today, CSL advances its vision for a more sustainable future by setting new, tangible targets for carbon emissions reductions. As part of the company's broader...

All business units will incorporate CSL name and branding to signify one company MELBOURNE, Australia, Aug. 10, 2022 /PRNewswire/ -- Global biotech leader CSL today announced that all business...